Etrasimod indicated for adult patients with moderate-to-severe diagnosis.
Everest Medicines revealed that Pfizer, its licensing partner, has received FDA approval for Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). Currently, Everest is in the process of conducting Phase III clinical trials of the medication in Asia with hopes of filing a new drug application.
"We congratulate our partner for achieving this significant milestone for UC patients who are in urgent need of new and effective treatment options and prefer the convenience of a once-daily pill. Etrasimod is a proven advanced treatment with a favorable safety profile." said Rogers Yongqing Luo, CEO, Everest Medicines, in a company press release. "Everest will advance our late-stage study as quickly as possible toward registration in China and other Asian markets as the incidence of ulcerative colitis has been rapidly increasing in the region in recent years."
Reference: Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis. PR Newswire. October 15, 2023. Accessed October 16, 2023. https://www.prnewswire.com/news-releases/everest-medicines-licensing-partner-pfizer-announces-us-fda-approves-etrasimod-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301956907.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.